DS-7300

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Prostate, Congress, Patient, Sustainable development, Lung cancer, Index (publishing), Immunoglobulin G, Safety, Head, Adult, Dehydration, Causality, Breast, Breast cancer, Chills, Bendell, Progression-free survival, Interstitial lung disease, Plexxikon, Research, Bachelor of Pharmacy, Oncology, Thought, Bladder cancer, DXD, CRO, Veni, vidi, vici, Fatigue, Endometrial cancer, ILD, MD, ADC, Anemia, Cancer, Squamous cell carcinoma, Lymphocyte, Laboratory, Vomiting, Appetite, European Society for Medical Oncology, Death, Cardiovascular disease, Senior, MTD, Sarah Cannon Research Institute, Melanoma, Quality of life, Technology, Oncotarget, Doctor of Philosophy, PRS, RDE, Cleavage, Nausea, Daiichi Sankyo, Diarrhea, Fever, Lung, Pharmaceutical industry, Medical imaging, Fine chemical, Silviculture, B7-H3, the DS-7300 Study, DS-7300, Daiichi Sankyo in Oncology, B7-H3, THE DS-7300 STUDY, DS-7300, DAIICHI SANKYO IN ONCOLOGY

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).

Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute

Retrieved on: 
Thursday, October 31, 2019
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health, Pharmaceutical industry, Articles, Clinical research, Life sciences, Drug discovery, Hospital Corporation of America, Sarah Cannon Research Institute, Clinical trial, Drug development, Contract research organization, the Study, DS-7300, Daiichi Sankyo Cancer Enterprise, Daiichi Sankyo, Sarah Cannon Research Institute

Based on our preclinical assessments, the trial will focus initially on patients with non-small cell lung, head and neck, esophageal, and other cancers.

Key Points: 
  • Based on our preclinical assessments, the trial will focus initially on patients with non-small cell lung, head and neck, esophageal, and other cancers.
  • Sarah Cannon Research Institute is one of the worlds leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom.
  • Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors through its oncology-focused contract research organization (CRO), Sarah Cannon Development Innovations.
  • As the CRO of Sarah Cannon, it leverages expert physician leadership to design and implement clinical trials that effectively and efficiently lead to rapid clinical development decisions.